Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
The Mesoblast Limited (ASX:MSB) share price has sunk around 10% after providing an update.
The Mesoblast Limited (ASX: MSB) share price could soar today on news from the US FDA.
The share price of biotechnology company Imugene Limited (ASX: IMU) has been on a tear this year. Here’s why the Imugene share price is flying.
The S&P/ASX 200 (INDEXASX:XJO) is tipped to open higher on Monday. Commonwealth Bank (ASX:CBA) and Mesoblast (ASX:MSB) shares are in the news.
The Mesoblast Limited (ASX:MSB) share price is going nuts this morning after announcing a deal with Novartis (SWX:NOVN).
The Mesoblast Limited (ASX:MSB) share price is surging this morning after making an announcement about its COVID-19 trial.
It has been an absolute rollercoaster ride for anyone who holds shares in Mesoblast Limited (ASX: MSB) this year. Is it time to buy in?
Novonix Ltd (ASX:NVX) was the most-traded stock on the ASX last week, overtaking some of the more well-known names such as Brainchip (ASX:BRN) and Zip Co (ASX:Z1P).
The Mesoblast Limited (ASX:MSB) share price could suffer after the FDA’s decision about remestemcel-L.
